Myelodysplastic syndromes (MDS) frequently progress to acute myeloid leukemia (AML); however, the cells leading to malignant transformation have not been directly elucidated. As progression of MDS to AML in humans provides a biological system to determine the cellular origins and mechanisms of neoplastic transformation, we studied highly fractionated stem cell populations in longitudinal samples of patients with MDS who progressed to AML. Targeted deep sequencing combined with single-cell sequencing of sorted cell populations revealed that stem cells at the MDS stage, including immunophenotypically and functionally defined pre-MDS stem cells (pre-MDS-SC), had a significantly higher subclonal complexity compared to blast cells and contained a large number of aging-related variants. Single-cell targeted resequencing of highly fractionated stem cells revealed a pattern of nonlinear, parallel clonal evolution, with distinct subclones within pre-MDS-SC and MDS-SC contributing to generation of MDS blasts or progression to AML, respectively. Furthermore, phenotypically aberrant stem cell clones expanded during transformation and stem cell subclones that were not detectable in MDS blasts became dominant upon AML progression. These results reveal a crucial role of diverse stem cell compartments during MDS progression to AML and have implications for current bulk cell-focused precision oncology approaches, both in MDS and possibly other cancers that evolve from premalignant conditions, that may miss pre-existing rare aberrant stem cells that drive disease progression and leukemic transformation.
evolution at the stem cell level, which is crucial for MDS pathogenesis and progression to sAML, has not yet been directly examined.
To obtain direct insights into the pathogenesis of MDS and progression to sAML at the stem cell level, we utilized longitudinal, paired samples from seven patients with MDS who had later progressed to sAML (Supplementary Table 1 ). For both MDS and paired sAML samples, we utilized multiparameter fluorescenceactivated cell sorting (FACS) to fractionate phenotypically defined malignant stem cells (MDS-SC, AML-SC) and premalignant stem cells (pre-MDS-SC, pre-AML-SC) as well as blast populations (MDS blasts, AML blasts) ( Fig. 1a and Supplementary Figs. 1 and 2) . Specifically, we isolated hematopoietic stem and progenitor cells (HSPC, Lin − CD34 + CD38 − ) expressing at least one of the LSC markers (CD45RA, CD123, or IL1RAP) that were previously identified [15] [16] [17] [18] to enrich for MDS-SC, AML-SC ( Supplementary Fig. 1a ). At the same time, we isolated HSPCs that were triple-negative for CD45RA, CD123, and IL1RAP to enrich for premalignant pre-MDS-SC, pre-AML-SC ( Supplementary Fig. 1a ). We observed significant expansion of the phenotypic malignant stem cell population within the total HSPC population during progression from MDS to sAML; this population increased from 30.3% (MDS) to 66.9% (sAML) on average ( P < 0.001; Supplementary Fig. 1b,c) . Xenotransplantation of phenotypic MDS-SC led to predominantly myeloid engraftment (CD33 + ) compared to pre-MDS-SC (73.2% versus 11.5%; Supplementary Fig. 3b ,c), whereas phenotypic pre-MDS-SC resulted in significantly higher lymphoid engraftment (CD19 + ) compared to MDS-SC (82.4% versus 18.8%; Supplementary  Fig. 3b ,c). Similar findings were obtained upon xenotransplantation of sorted pre-AML-SC and AML-SC ( Supplementary Fig. 3d-f ). Moreover, consistent with previous reports 19, 20 , we also observed significantly lower clonogenicity ( Supplementary Fig. 4a,b ) and increased myeloid bias ( Supplementary Fig. 4c,d ) of sorted MDS-SC and AML-SC compared to pre-MDS-SC and pre-AML-SC, respectively. These data indicate that CD45RA/CD123/IL1RAP-expressing HSPC are indeed enriched for malignant stem cells, and CD45RA/ CD123/IL1RAP triple-negative HSPCs are enriched for premalignant stem cells in MDS and AML.
To prospectively analyze clonal evolution at the stem cell level during the progression of MDS to AML, all seven cell populations (pre-MDS-SC, MDS-SC, MDS blasts; pre-AML-SC, AML-SC, AML Multiparameter cell sorting was used to fractionate premalignant stem cells (pre-MDS-SC, pre-AML-SC), malignant stem cells (MDS-SC, AML-SC), and blast populations (MDS blasts, AML blasts). Nonhematopoietic cells (CD45-negative) were used as germline control for detection of somatic mutations and copy number changes. Selected mutations in each population were further examined with single-cell sequencing. b, Representative distribution of CCFs in stem cells (pre-MDS-SC and MDS-SC; or pre-AML-SC and AML-SC) and blasts of patient P7028, showing that stem cells had more mutations at a lower frequency than blasts for both the MDS and sAML stages, respectively. The violin plot shows the frequency distribution (kernel density) of clonal mutations (orange) and subclonal mutations (gray). c,d, Burden of clonal (c) and subclonal (d) mutations in stem cell and blast populations at the MDS (P = 0.0002) and AML (P = 0.005) stages across patients (n = 7). e, Clonal composition of stem cell and blast populations in MDS (upper left, lower left) and sAML (upper right, lower right), respectively, in patient P7028. Based on the VAFs, mutations covered by > 30× are clustered as clones and denoted with the same color. Mutation was denoted with gray if the estimated possibility of the mutation to be clustered in the subclone was lower than 0.95. f, Number of mutation clusters, as estimated by VAFs of mutations, in stem cells and blasts at the MDS (left, P = 0.013) and AML (right, P = 0.021) stages across all patients studied (n = 7). Black bar represents the mean of clone numbers across the samples. g,h, Clonal composition of stem cell and blast populations at MDS (left, P = 0.0047) and AML (right, P = 0.02) estimated by CCFs of mutations (n = 7). For e and g, from bottom to top, the horizontal lines mark sequencing depths of 5× , 10× (not labeled), 20× , 50× , 100× (not labeled), 200× , 500× , and 2,000× . Unless specified otherwise, data are mean ± s.e.m. * P < 0.05, ** P < 0.01, ***P < 0.001 (two-tailed paired Student's t-test).
Letters

NATure MeDiCiNe
blasts; nonhematopoietic germline control) from the same patient with MDS and sAML were subjected to targeted deep sequencing with a custom panel containing the most frequently altered genes in hematologic malignancies 21 and other recent genes of interest involved in the development of MDS and AML ( Fig. 1a and Supplementary Table 2 ). For each of the target genes, we included all of the exons, 5′ and 3′ UTRs, and the 1,000-base-pair (bp) up-and downstream regions of the gene. Prior to sequencing, we performed whole-genome amplification (WGA) of the sorted cell populations, which was shown not to distort the variant allele frequency (VAF) of mutations ( Supplementary Fig. 5a,b ). Targeted sequencing achieved consistent coverage across different cell populations in the same patient, ranging from 300× to 1,000× between patients ( Supplementary Fig. 5c ). To assess mutation patterns across different cell populations, we detected somatic mutations in each of the cell populations through comparison to the germline control ( Fig. 1a and Supplementary Table 3 ), and validated the selected mutations by Sanger sequencing ( Supplementary Fig. 5d,e ). Interestingly, we found a significantly higher number of mutations, in both exonic and nonexonic regions, in stem cells than in blasts in both MDS and sAML ( Supplementary Fig. 5f -h). Thereafter, we calculated the cancer cell fraction (CCF) within each cell population, considering VAF, purity, and ploidy as previously described 22 ( Supplementary Fig. 6a ). Mutations were defined as 'clonal' if the 95% confidence interval of the CCF was greater than 0.95; otherwise, they were called 'subclonal' 22 . We found that, while the frequencies of clonal mutations were similar across the cell populations ( Fig. 1c and Supplementary Fig. 6 ), the frequency of subclonal mutations was significantly higher in stem cells than in blast cells in both MDS (4.9 ± 0.92 versus 2.1 ± 0.79 per megabase; P < 0.001) and AML (4.2 ± 1.6 versus 1.9 ± 1.6 per megabase; P < 0.01) ( Fig. 1d ). These results indicated that, in both MDS and sAML, stem cells possess higher subclonal complexity than blast cells. Previous studies have found associations of the intrinsic mutational processes in stem cells during life with various cancers, and the burden of mutations in tissue-specific stem cells is highly correlated with age 23, 24 . In addition, as several DNA repair pathways are dependent on cell cycling, relative quiescence may render stem cells vulnerable to accumulation of DNA damage during aging [25] [26] [27] . Consistent with this idea, we found that mutation patterns in both MDS and sAML stem cells were associated with DNA repair pathways in addition to association with age-related signatures ( Supplementary Fig. 7) .
To compare the subclonal diversity of stem cells versus blasts, we inferred the clonal architectures of stem and blast cells with Sciclone 28 , using VAFs ( Fig. 1e ,f) as well as CCFs ( Fig. 1g ,h) of mutations. Interestingly, compared to blast cells, stem cells had a significantly higher total number of inferred mutation clusters (ranging from 2 to 4 versus 1 to 3; P < 0.05) at the MDS and sAML stages ( Fig. 1e ,f). Consistent findings were obtained through clonality analyses using CCFs, in that stem cells had a higher number of mutation clusters compared to the blasts (3 to 5 versus 1 to 4; P < 0.01) ( Fig. 1g,h and Supplementary Fig. 8a -f). The difference was mainly attributable to a difference in number of non-dominant clones with lower CCFs ( Fig. 1g and Supplementary Fig. 8a-f ). Taken together, our results indicated that in both MDS and sAML, stem cell compartments have a higher subclonal diversity compared to blasts.
We next examined the patterns of clonal evolution during the progression from MDS to sAML of stem versus blast cell populations. Across all populations, premalignant stem cells, malignant stem cells, and blast cells, we identified shared mutations between MDS and sAML that either had high (clonal) or low (subclonal) CCFs ( Supplementary Fig. 9 ). Interestingly, our results also revealed substantially different patterns of clonal evolution between stem cell compartments and blast cells during MDS progression to sAML in several patients ( Supplementary Fig. 9 ). In addition, we found a somewhat variable extent of clonal evolution of pre-MDS-SC and MDS-SC in individual patients. This may also reflect the phenotypic heterogeneity of putative disease stem cells 29 , which will be interesting to study in larger cohorts of patients.
We next compared clonal evolution across all cell populations and during MDS to sAML progression longitudinally. In all the patients studied, we observed one dominant clone that was shared (denoted with orange) in stem cells and blast cells at both MDS and sAML stages ( Fig. 2a-g ). Within these dominant clones, we found mutations in genes (for example, TET2, EZH2, TP53, SETBP1, U2AF1, CSF1R, and KRAS) that are frequently observed in bulk cell sequencing studies of human MDS and AML 30, 31 , as well as in elderly individuals with clonal hematopoiesis-albeit typically at a low subclonal size [32] [33] [34] . Interestingly, both clonal shared mutations (for example TET2, EZH2, TP53, U2AF1, CSF1R, and KRAS) and subclonal shared mutations (for example KMT2C, NOTCH2, and FANCD2) were detectable in T cells ( Supplementary Fig. 10 ), indicating that these shared mutations are acquired early during MDS disease initiation and that the presence of these mutations in stem cells is still compatible with T cell differentiation. This is in line with a recent study that found clonal hematopoiesis-associated mutations, including DNMT3A, TET2, TP53, and SF3B1 in virtually all hematopoietic populations, including hematopoietic stem cells (HSCs), in elderly individuals 35 . Furthermore, two recent longitudinal studies of healthy individuals who eventually developed AML also detected mutations in some of the shared dominant genes (for example, TET2, TP53, and U2AF1) in peripheral blood DNA many years before the actual diagnosis of AML, and the mutations were associated with increased risk of developing AML 36, 37 .
In line with the results above ( Supplementary Fig. 8 ), we consistently identified more subclones at the stem cell level compared to blasts in all patients, again revealing distinct subclonal architectures between stem and blast cell compartments. Interestingly, in patient P7026, one subclone (colored red) was well detectable in pre-MDS-SC and MDS-SC, but had a frequency of only 2% in MDS blasts and then expanded to become the dominant clone across all populations upon progression to sAML ( Fig. 2c ). Moreover, in patients P7024 and P7030, we observed large subclones at the AML stages (colored red; Fig. 2a ,f). Most interestingly, these subclones were undetectable in MDS blasts, but were inferred at frequencies of 2-3% in MDS-SC ( Fig. 2a ,f). Taken together, these results suggested a potential model of nonlinear clonal evolution at the stem cell level during initiation of MDS and progression to sAML: the mutational process would generate a dominant clone as well as distinct subclones at the stem cell level, and only one or a few of these clones would become apparent at the bulk/blast level ( Supplementary Fig. 11 ).
To definitively determine the relationship between different subclones in the same population as well as clonal dynamics across all cell populations, we performed single-cell targeted sequencing of sorted stem and blast populations ( Supplementary  Fig. 12 ) with selected mutations from each of the inferred subclones ( Fig. 2) . We calculated the CCFs of mutations using the single-cell sequencing results and found significant correlation between the CCFs estimated by Hiseq of sorted cell populations and those determined by single-cell sequencing in all patients ( Supplementary Fig. 12d -h).
Targeted deep sequencing of sorted populations from patient P7024 had identified that clonal mutations in EZH2 and subclonal mutations (for example, KMT2C) were shared across all stem cell and blast populations (Fig. 3a, left and Supplementary Fig. 13a ). By single-cell sequencing, we found that EZH2 mutations were indeed present in the majority of cells across different populations, whereas KMT2C mutations resided in a subclone within EZH2-mutated cells (Fig. 3b ). Interestingly, mutations in HDAC4, GLI1, and RPL22 were present in only small subclones of MDS-SC and were not responsible for MDS blast generation or progression to sAML ( Fig. 3a-c) . Clonal prevalence 
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Early initiating, dominant mutations, for exampleTP53, TET2, and U2AF1
Early subclonal mutations, for example KMT2C, NOTCH2
Stem cell mutations associated with progression to AML, for example RUNX1, NRAS, ERG, ATRX, NTRK3, DUSP22 gives rise to a highly diverse subclonal architecture (indicated by different colors) in MDS-SC. Certain subclones (orange, for example with TP53, TET2, or U2AF1 mutations, 'clonal hematopoiesis') provide a shared basis for both MDS development (MDS blasts) as well as the formation of pre-AML-SC and AML-SC. However, pre-MDS-and MDS-SC acquire different additional mutations that then drive MDS blast formation or progression to sAML, respectively, in a nonlinear and rather parallel manner in all patients studied. In four (P7024, P7026, P7027, and P7030) out of seven cases studied, we identified that the dominant clone at the sAML stage originated from a clone (red, for example with RUNX1, NRAS, or ERG and ATRX mutations) that was detectable in pre-MDS and/or MDS-SC, but was undetectable in MDS blast cells. These results indicate that MDS-SC leading to the generation of MDS blasts can be different from those contributing to the progression to sAML, highlighting a crucial role of the entirety of the diverse MDS-SC pool in sAML disease progression, which has implications for current bulk cell-focused diagnostic and therapeutic precision oncology approaches. b, Schematics of different models of MDS and sAML development and progression. In comparison to the linear model (top), which suggests serial mutation accumulation during disease progression, our data support a model of parallel clonal evolution at the stem cell level during development of MDS and progression to sAML (bottom). Seven out of seven cases showed a highly diverse pool of (pre-)MDS-SC as the basis of MDS and sAML development; in four out of seven patients, we found very early branching at the (pre-)MDS-SC level towards progression to AML-SC, leading to distinct clonal composition between MDS and AML bulk cells; and three out of seven patients showed a pattern of slightly later branching (dashed red arrows) leading to more similar clonal composition between MDS and AML bulk cells compared to the early-branching cases.
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Co-mutations in NTRK3 and DUSP22 co-occurred in AML stem and blast cell populations within EZH2-mutated cells, but were not detectable in MDS blast cells; strikingly, however, single-cell sequencing demonstrated small subclones containing these mutations within pre-MDS-SC and MDS-SC stem cell compartments (Fig. 3b,c) . In AML populations, we identified mutations of ATM and HOXC11 within the NTRK3-and DUSP22-mutated stem cells, whereas mutation of PML was observed in only a small subclone of NTRK3-and DUSP22-mutated blast cells (Fig. 3a-c) . Taken together, the findings obtained by single-cell sequencing lead to a patient-specific model of clonal evolution across different stem and blast populations in MDS and sAML (Fig. 3b,c) . In this patient, mutations in EZH2 were acquired early in the founding clone at the MDS stage and acquisition of additional mutations in NTRK3 and DUSP22 was associated with progression to sAML (Fig. 3c ), while MDS blasts were characterized by different co-mutations. Thus, sAML developed from a rare subclone contained within MDS-SC and not through further evolution of MDS blasts (Fig. 3c) .
In patient P7026, we detected a shared TP53 mutation in the majority of single cells across all cell populations (Fig. 3d,e and Supplementary Fig. 13b ). We also observed a less frequent but stable subclone with co-mutations of NOTCH2 and PDE4DIP within the TP53-mutated cells ( Figs. 2b and 3d,e ). On the other hand, ERG and ATRX co-mutations were present in a more frequent (dominant) clone within pre-MDS-SC and MDS-SC ( Fig. 3d,e ) that was distinct from the subclone with NOTCH2 and PDE4DIP co-mutations. Interestingly, this subclone was nearly undetectable (VAF = 1.95%) in MDS blast bulk cell sequencing and undetectable in MDS blast single-cell sequencing ( Figs. 2b and 3d ,e) but became dominant in all sAML stem and blast cell populations ( Fig. 3d-f ), again demonstrating that the subclones contributing to the generation of MDS blasts were different from those contributing to the progression to sAML (Fig. 3e,f) . Single-cell sequencing also identified two distinct subclones within the pre-MDS-SC subclone with ERBB3 mutation, one with co-mutations of AKT1 and NR4A3 and another with a mutation of DDX41 (Fig. 3e ). However, none of these specific subclones persisted in MDS blasts or during sAML progression. Taken together, in this patient the dominant clone present in sAML stem and blast cells developed from a clone within the MDS-SC that was, however, undetectable in MDS blasts (Fig. 3f ). Mutations of ERG are relatively rare in MDS and AML, and mutations of ATRX are also infrequent and found in 0.2-0.8% of the patients with MDS, but they are higher in the MDS subtype associated with α -thalassemia 38, 39 . In future studies, it will be interesting to assess whether these mutations play functional roles in promoting the progression of MDS to sAML.
In patient P7030, we identified two clonal mutations in U2AF1 Q157R and U2AF1 S34F that were shared across all populations (Figs. 2f and 3g,h and Supplementary Fig. 13d ). We also identified a relatively large subclone within the U2AF1-mutated cells with mutations of PAX3, RNF213, and NIN that was shared in all MDS populations but that did not appear at the sAML stages (Figs. 2f and 3g,h). A mutation in NRAS was detectable only in MDS-SC (VAF = 6.5%; Supplementary Fig. 13d ) at the MDS stage (and not in MDS blasts) and resided in a subclone within U2AF1-mutated cells that was distinct from the PAX3-mutated subclone (Fig. 3h) . Interestingly, this NRAS-mutated MDS-SC subclone then expanded at the sAML stage ( Figs. 2f and 3g) , accompanied by the acquisition of an additional mutation in PPP2R1A (VAF = 0% at MDS-SC; Supplementary Fig. 13d ). In this patient, progression to sAML originated from a small subclone of U2AF1-mutated MDS-SC bearing the NRAS mutation ( Fig. 3g-i) . Similarly, in patient P7027, we observed that AML progression was associated with a small subclone of MDS-SC with RUNX1 mutation ( Supplementary Fig. 14) . Both NRAS and RUNX1 mutations are recurrent in patients with MDS and AML, with markedly higher incidence in high-risk MDS and AML 14, 30, 31 , and NRAS mutations are rarely found at initial diagnosis 14, 40 . Our results suggest that NRAS and RUNX1 mutations may pre-exist at least in some patients, and they may reside in rare stem cell subclones at a very early disease stage.
Interestingly, in comparison with the patients shown above, we observed slightly more stable clonal evolution at the level of both stem and blast cells in patients P7025 and P7028 (Fig. 2b,e and Supplementary Fig. 15a-d) . While most of the clonal mutations were shared between MDS and sAML (for example, TET2 and SETBP1 in P7028; TP53 in P7025), we again observed MDS-and AML-specific mutations, respectively, in particular within MDS-SC and AML-SC (Fig. 2b,e and Supplementary Fig. 15a-d) . In patient P7031, we identified clonal mutations on CSF1R and KRAS that were shared across all cell populations ( Fig. 2g and Supplementary  Fig. 15e,f) . We also observed a larger subclone with mutations in RNF213, RUNX1, and IDH2 that were shared in all MDS populations as well as pre-AML-SC but that did not contribute to the generation of AML blasts ( Fig. 2g and Supplementary Fig. 15e-g) . A U2AF1 Q157R mutation was detected in MDS-SC and MDS blast cells with CCFs of 0.26 and 0.17, respectively, and cells with this mutation expanded upon the progression to sAML with CCFs ranging from 0.51 to 0.61 ( Supplementary Fig. 15e,f) . Overall, compared to patients P7024, P7026, P7027, and P7030 ( Fig. 3c,f,i) , the results for P7025, P7028, and P7031 revealed a model of slightly later branching of MDS-SC towards progression to sAML ( Supplementary  Fig. 15b,d,g) .
In summary, we chose a strategy of combining rigorous cell sorting with targeted deep sequencing of both stem and blast cells from patients with MDS who progressed to sAML, which resulted in a hitherto unprecedented resolution at the stem cell level (effective depth equivalent to what could only be achieved by 250,000× to 5,000,000× deep bulk sequencing, as a result of ~0.01-0.2% frequency of sorted stem cells and average sequencing depth of approximately 500× ). By both ensemble and single-cell sequencing of both stem cell and blast populations of MDS and matched sAML, we found that stem cells at the MDS stage have a significantly higher complexity of subclonal mutations compared to blast cells (Fig. 4a ). Subclonal mutations mostly resided within the dominant clone with early mutations (for example, TET2, TP53, and U2AF1) but can dramatically increase in size towards progression to sAML, suggesting that an upfront distinction at the MDS stage of 'dominant' and 'passenger' clones/mutations solely based on clone size may not have disease pathogenetic or predictive relevance. Our findings reveal the crucial role of a diverse stem cell pool regarding full transformation and MDS blast cell generation, as well as progression to sAML, in a nonlinear and rather parallel manner (Fig. 4 ). These findings have implications for currently employed bulk cell-focused precision oncology approaches and provide a rationale to consider mutational examination of fractionated stem cell populations in patients with MDS, and possibly other cancers arising from premalignant conditions, to more comprehensively assess pharmacologically 'actionable' mutations relevant to later disease progression and development of AML.
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Methods
Multiparameter high-speed FACS of stem and blast cells from patient samples.
Bone marrow (BM) samples from seven patients with MDS and matched sAML were obtained, after written informed consent, from Montefiore Medical Center/ Albert Einstein Cancer Center (Institutional Review Board no. 11-02-060E; for patient characteristics see Supplementary Table 1 ). All studied patients received treatment with hypomethylating agents between MDS and AML progression. Frozen BM aspirates were thawed in a water bath at 37 °C and resuspended in Iscove's modified Dulbecco's medium (IMDM) supplemented with 2% fetal bovine serum (FBS). After repeated washes with IMDM 2% FBS, cells were resuspended in MACS buffer (phosphate buffered saline supplemented with 0.5% bovine serum albumin and 2 mM EDTA, pH 7.2). Thereafter, CD34 + were immunomagnetically separated with Miltenyi MACS technology (130-046-702, Miltenyi Biotec) according to the manufacturer's protocol. CD34 + -enriched cells were stained for 30 min on ice with antibodies: PE-Cy5 (Tri-Color)-conjugated lineage markers (CD2, CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, CD56, Glycophorin A), APC-conjugated blast marker CD33, and hematopoietic stem and progenitor markers (Pacific blue CD34, PE-Cy7 CD38, FITC CD45RA, Alexa Fluor 700 CD123, and PE IL1RAP). A list of antibodies is provided in Supplementary  Table 4 . We used Lin − CD34 + CD38 − CD45RA − CD123 − IL1RAP − to enrich for pre-MDS-SC or pre-AML-SC and Lin − CD34 + CD38 − (CD45RA + and/or CD123 + and/or IL1RAP + ) to enrich for MDS-SC or AML-SC. Cells were also stained with PE CD45, APC CD33, and pacific orange CD4 to isolate blast cells (CD45 + CD33 + ), T cells (CD45 + CD4 + ), and nonhematopoietic cells (CD45 − ) as germline control for somatic variant calling. Interpatient heterogeneity in the profile of surface markers for disease-relevant stem cells has been observed in patients with MDS and AML 41, 42 , suggesting that there is a need to utilize a combination of surface markers. In addition, the coexistence of residual normal HSC and numerous subclones of partially transformed pre-MDS-SC as well as fully transformed MDS-SC makes their distinction challenging based on phenotypic markers in individual patients. Isolation of cell populations based on phenotypic markers remains a relative enrichment strategy, which requires functional and genetic validation. Xenografting experiments with the respective populations ( Supplementary Fig. 3 ) demonstrated functionality consistent with pre-MDS-SC versus MDS-SC properties. In addition, the fact that the sorting strategy described here was able to detect relevant mutations in pre-MDS-SC and MDS-SC indicates the validity of the strategy, at least in this cohort of patients. It will be interesting to further validate this sorting scheme for pre-MDS-SC in larger patient cohorts in the future.
Methylcellulose assay. To assess the differentiation potential of phenotypic premalignant stem cells (pre-MDS/AML-SC) and malignant stem cells (MDS/ AML-SC), cells were FACS-sorted from additional patients with the same strategy ( Supplementary Fig. 1a ) and plated in HSC003 methylcellulose medium according to the manufacturer's recommendation (R&D Systems). Colonies of different hematopoietic lineages were scored 2 weeks after plating using an Inverted Infinity and Phase Contrast Microscope (Fisher Scientific). In addition, to examine the expression of lineage makers, methylcellulose medium was dissolved in PBS to dissociate the colonies into a single-cell suspension. Cells were stained with antibodies against CD14, CD15, and CD235a on ice for 30 min and then analyzed on a BD FACSAria II system. Xenotransplantation assays. Bone marrow samples from additional patients with MDS or AML (unpaired) were processed and stained for surface markers for premalignant stem cells (pre-MDS/AML-SC) and malignant stem cells (MDS/AML-SC), as described above ( Supplementary Fig. 1a ). Thereafter, 30,000-100,000 sorted cells were washed with and resuspended in Hank's Balanced Salt Solution (HBSS) and transplanted into nonirradiated NOD,B6.SCID Il2rγ −/− Kit W41/W41 (NBSGW) immunocompromised mice (aged 6-8 weeks) via retro-orbital injection 43 . All experiments conducted on mice were approved by the Institutional Animal Care and Use Committee at Albert Einstein College of Medicine (protocol no. 2016-0103). Engraftment analysis of patient-derived cells was performed from 12 weeks after transplantation. Mouse bone marrow cells were incubated with ammonium chloride potassium buffer for 1 min on ice, and then stained for surface markers for mouse leukocytes, including CD45.1, and markers for human leukocytes, including CD45, CD19, and CD33. The stained cells were then analyzed on a BD FACSAria II system. While several studies have found some remaining lymphoid reconstitution of MDS/AML-SC in irradiated recipient mice in a subset of patients 44, 45 , many others found an exclusively myeloid output of MDS/AML-SC 8, 15 . The partially lymphoid engraftment observed in our study could be due to the nonirradiated NBSGW xenograft model we utilized 43 , as myeloid-biased engraftment of stem cells seems to be most pronounced in irradiation-conditioned transplantation assays 46, 47 .
Whole-genome amplification. WGA was performed with REPLI-g kit (Qiagen), which utilizes the proofreading enzyme Phi 29 polymerase to achieve high-fidelity amplification of genomic DNA 48, 49 . For sorted samples with yield cell number larger than 1,000, cells were washed with PBS and then resuspended with 5 µ l of sterile PBS. The REPLI-g mini kit was used according to the manufacturer's protocol. For sorted samples with fewer than 1,000 cells or for single-cell analysis, cells were sorted into 5 µ l PBS, and REPLI-g single-cell kit (Qiagen) was used for WGA according to the manufacturer's protocol. For DNA samples, we used 1-10 ng DNA as input and REPLI-g mini kit (Qiagen) was used for WGA. All the products of WGA were purified with Agencourt AMPure XP beads (Beckman Coulter) to remove residual dNTP, primers, and random products < 100 bp.
Targeted sequencing with HiSeq 2500. From the same patient, seven cell populations (pre-MDS-SC, MDS-SC, MDS blasts; pre-AML-SC, AML-SC, AML blasts; nonhematopoietic germline control) were subjected to targeted sequencing of a 504-gene customized panel containing all the genes in the FoundationOne Heme panel 21 as well as other genes of interest involved in the development of MDS and AML (full list of genes is provided in Supplementary Table 2 ). For each of the target genes, we included all the exons, 5′ and 3′ UTRs, as well as the 1,000-bp upand downstream regions of the gene. For targeted sequencing, 500 ng of DNA was used as input for sequencing with an Illumina HiSeq 2500 system (Illumina). In brief, DNA was fragmented by a Covaris ultrasonicator (Covaris) with a target size of ~200 bp, followed by end repair and A-tailing with KAPA LTP library preparation kit for Illumina platforms (Kapa Biosystems) according to the manufacturer's instructions. Thereafter, we linked the DNA products with Illumina TrueSeq sequencing adapters and performed size selection with dual-SPRI beads (Beckman Coulter). Next, we performed eight cycles of pre-capture ligation mediated (LM)-PCR with the adapter-ligated DNAs according to the user's guide for NimbleGen SeqCap EZ Library (Roche NimbleGen). Afterwards, LM-PCR products of different cell populations from the same patient were incubated together for 72 h with NimbleGen SeqCap EZ probes (Roche NimbleGen). Hybridization products were then incubated with capture beads at 47 °C for 45 min, followed by washing and elution with PCR-grade water according to the manufacturer's protocol. Captured DNAs were then amplified with eight cycles of post-capture LM-PCR according to the user's guide for NimbleGen SeqCap EZ Library (Roche NimbleGen). Finally, DNA products were purified with Agencourt AMPure XP beads (Beckman Coulter) and then subjected to massively parallel sequencing (100 bp paired-end) on the HiSeq 2500 platform according to the manufacturer's instructions.
Analysis of sequencing data.
We assessed the quality of the raw sequencing data from HiSeq with FastQC v0.11.4 (https://www.bioinformatics.babraham.ac.uk/ projects/fastqc/). Reads contaminated with sequencing adapter and those of low quality were removed by Trim Galore 0.4.1 using the default parameters (https:// www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Thereafter, we performed genome alignment (hg19) using Bowtie2 v2.2.9 (ref. 50 ). Alignment results were processed as described in GATK best practice for detection of somatic mutation recommended by the Broad institute 51 . Briefly, duplicated reads were marked with a Picard toolkit (http://broadinstitute.github.io/picard/). Thereafter, indel realignment and base recalibration were performed for each of the individual samples with GATK v3.7 (ref. 51 ). Moreover, we performed a second run of indel realignment with merged samples from the same human patient to remove falsepositive mutations caused by alignment artifacts. After preprocessing of the reads, sequencing coverage of each sample was calculated with the DepthOfCoverage module of GATK. For detection of somatic mutations, we used Mutect2 of GATK v3.7 comparing each of the cell populations to the matched germline control with the default parameters 52 . We then merged all the Mutect2 results passing the filter from the same human patient to generate a combined set of mutations for each of the patients. FreeBayes v0.9.20 was used to perform joint variant calling with all samples from the same human patient 53 , using the parameters of -m 1 -q 3 -F 0.05 -C 2 -U 3 -read-indel-limit 2 -min-coverage 20. We also excluded the variants from FreeBayes results with quality score < 10. Thereafter, high-confidence mutations consistently detected by both Mutect2 and FreeBayes were used for downstream analysis. In addition, to address potential false-negatives due to tumor cell contamination of germline controls, we also included somatic mutations reported in MDS or AML by more than two groups in the COSMIC database (http://cancer.sanger.ac.uk/cosmic). Thereafter, we excluded the mutations that were: (i) covered less than 20× in germline control or test cells; (ii) supported by < 3 reads or 5% of the reads in test samples; (iii) reported in dbSNP database (SNPs v147), 1000 genome phase 3, or ExAC database 1.0 with population frequency > 0.5%. To further remove mutation artifacts caused by sequencing context of low complexity, we excluded mutations that were: (i) located within 10 bp of an indel; (ii) within 20 bp of another single-nucleotide variant (SNV); (iii) less than 5 bp to microsatellite or simple repeats of the UCSC database (https://genome.ucsc.edu); (iv) less than 5 bp to homopolymer (> 5 bp). Thereafter, mutations were annotated using the hg19 database by SnpEff v4.1k (ref. 54 ).
For analysis of mutation signatures, we combined the somatic mutations in each cell population from the five patients sequenced and examined the pattern of mutation signatures with deconstructSigs 1.8 with the signatures defined previously 55 . The weight of each signature was normalized by the number of times each trinucleotide context was observed in the targeted regions.
Clonal analysis. VAF for each mutation was calculated by the number of reads supporting the variant divided by total reads, using the FreeBayes output. Moreover, sample purity and local copy number variation (CNV) were estimated by the FACETS v0.5.6 package of R v3.2.3 (ref. 56 ), which utilizes the read counts of both heterozygous and homozygous single-nucleotide polymorphism (SNP) Letters NATure MeDiCiNe loci. In brief, for each of the samples, we first extracted the read counts of reference and alternative alleles of each SNP reported in dbSNP (Common SNPs v147) or 1000 genome SNP phase 3 database with population frequency larger than 5%. Thereafter, the read count information of the SNP loci covered by at least 20× in the targeted sequencing of each sample was subjected to FACETS as input to estimate the purity and CNV using the default parameters. Thereafter, the CCF of each mutation was estimated using the VAF, purity, and local CNV of the mutation as described before 22 . Mutations were defined as 'clonal' if the 95% confidence interval of CCF overlapped with 0.95, otherwise being defined as 'subclonal. ' To investigate the clonal architecture, both VAFs and CCFs of mutations covering > 30× were subjected to SciClone v1.1.0 allowing a maximum cluster number of 10 (ref. 28 ). When comparing the clonal architecture of different cell populations of the same patient, we first generated a combined list of mutations that covered at least 20× in all samples, then subjected the VAFs of mutations in different populations to SciClone analysis. We excluded the mutations in the cluster if the estimated possibility of the mutation being clustered in the subclone was lower than 0.95. In addition, to examine the clonal relationship between different cell populations in the same samples, we performed phylogenetic reconstruction by LICHeE v1.0 using VAFs of the mutations and the prevalence of each subclone in the samples estimated by SciClone, with the standard parameters (-maxVAFAbsent 0.005 -minVAFPresent 0.005 -n 0) recommended by the LICHeE instructions 57 . Thereafter, the results of phylogenetic relationships determined by LICHeE were visualized by the TimeScape v1.0.0 package 58 .
Single-cell targeted sequencing. After staining of surface markers, single cells were directly deposited, using a MoFlo Astrios EQ system (Beckman Coulter), into a 96-well PCR plate containing 5 µ l of sterile PBS per well. Thereafter, WGA was performed using a Repli-g single-cell kit (Qiagen) according to the manufacturer's protocol. WGA products were purified with Agencourt AMPure XP beads (Beckman Coulter). For targeted sequencing, we designed primers for each mutation target using Primer 3, with product sizes < 200 bp (Supplementary Table 5 ). Target-specific primers were linked with the Fluidigm forward (5′ -ACACTGACGACATGGTTCTACA-3′ ) and reverse (5′ -TACGGTAGCAGAGACTTGGTCT-3′ ) common sequence (CS) tag for downstream barcoding. To preamplify the DNA of target regions, we first performed specific target amplification (STA) of WGA products using FastStart Taq DNA Polymerase (Roche). In brief, all CS-tagged primers for the same sample were pooled and diluted to make a final concentration of 1 µ M for each primer. The amplification mix for each sample was prepared as follows: 0.5 µ l of 10× reaction buffer with MgCl 2 , 0.5 µ l MgCl 2 , DMSO, 10 mM nucleotide mix, 0.2 µ l FastStart polymerase, 1 µ l 1 µ M primer pool, and 10 ng DNA. Next, PCR amplification was performed as follows: 95 °C for 10 min; 2 cycles of 95 °C for 15 s and 60 °C for 4 min; 10 cycles of 95 °C for 15 s and 72 °C for 4 min. As a negative control, we included a no-template control (NTC) in the STA experiment. Thereafter, 10 µ l of each STA product diluted to 100 ng µ l -1 was transferred to half of a new 96-well plate (47 single-cell samples plus one NTC per plate), and treated with ExoSAP-IT (Affymetrix) for purification. For primer preparation, each primer pair was diluted to 1 µ M in the 96-well plate with Fluidigm Access Array loading reagent (Fluidigm). Thereafter, plates of STA products and primer pairs were loaded onto 48.48 integrated fluidic circuits (IFC) in a Biomark HD system (Fluidigm). Each of the STA products was mixed with each primer pair, and PCR amplification was performed in the IFC array according to the manufacturer's protocol. Thereafter, PCR products of the same sample were pooled together, and sample barcoding PCR was performed with primers containing the barcode sequence (Fluidigm) and Illumina sequencing adapter (Illumina). We assessed the quality of the barcoded samples with a 2100 Bioanalyzer (Agilent), then all samples were pooled at equal ratios and subjected to sequencing with the MiSeq (150 bp paired-end) system according to the manufacturer's protocol (Illumina).
For analysis of the MiSeq data, we trimmed reads with CS tag and reads contaminated with the sequencing adapter, and we also removed reads of low quality by Trim Galore using the default parameters. Thereafter, we performed genome alignment to hg10 with BWA-MEM v0.7.15 (ref. 59 ), and then variant calling with FreeBayes. We also manually confirmed each target mutation with the Integrative Genomics Viewer, with mutations with > 20% supporting reads (covering at least 5× ) being considered positive.
T cell receptor sequencing. To assess the diversity of the T cell receptor (TCR) repertoire, we extracted total RNA from T cells isolated from the patient samples, as well as cord blood samples as healthy controls, using an RNeasy Micro Kit (Qiagen) according to the manufacturer's protocol. We used 50 ng of total RNA as input for first-strand cDNA synthesis with the reagents supplied in the SMARTer Human TCR a/b Profiling Kit (Takara Bio USA) according to the manufacturer's protocol. Thereafter, a first round of PCR (PCR 1) was performed with SMART Primer 1 to link the Illumina Read 2 sequence to the cDNA, and TCRα and TCRβ primers, to specifically amplify the variable regions and constant regions of TCRα and TCRβ cDNA. The PCR 1 reaction was performed for 21 cycles with a preheated thermal cycler (C1000, Bio-Rad) according to the manufacturer's protocol. Next, 1 µ l of PCR1 product was subjected to second-round PCR (PCR 2), which was performed with TCRα and TCRβ Human Primer 2 Reverse HT Index primers (D501) to link the Illumina Read 1 sequence and P5-i5 index sequences. In addition, for different samples, we used different TCR Primer 2 Forward HT Index primers for the linkage of Illumina P7-i7 index sequences. The PCR 2 reaction was performed for 20 cycles with a preheated thermal cycler according to the manufacturer's protocol. Lastly, the products of PCR 2 were purified using Agencourt AMPure XP beads (Beckman Coulter) with a double-size selection approach according to the manufacturer's instructions. The quality and quantity of the purified products (sequencing-ready libraries) were assessed with a 2100 Bioanalyzer (Agilent) and Qubit 2.0 Fluorometer, respectively. Sequencing was performed on an Illumina MiSeq sequencer with paired-end, 300-bp reads. For analyses of the sequencing data, the first 30 bp of read 2, which includes the SMART primer sequence, was trimmed with Trim Galore. The trimmed data was then analyzed with LymAnalyzer 1.2.2 separately for TCRα and TCRβ genes 60 . We then calculated the frequency of each Vα or Vβ gene segment relative to the total sequences mapped to the Vα or Vβ genes.
Statistical analysis. Data are presented as mean ± s.d. if not otherwise specified. Student's t-test was performed with GraphPad Prism 7.0, as indicated. Pearson correlation coefficient r and statistical significance P values were calculated with the built-in cor.test function of R, and data were visualized with the ggplot2 package of R.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Validation
Standard FACS antibodies obtained from widely used commercial providers were used in this study. Catalog numbers and clones are given in the Supplementary Table 4 . All antibodies were validated through positive and negative control stainings, as well as isotype control antibodies.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
For transplantation assay, we used NOD,B6.SCID Il2rγ−/−KitW41/W41 (NBSGW) immunocompromised female mice at the age of 6-8 weeks
Wild animals
No wild animals were used in this study.
Field-collected samples
No field-collected samples were used in this study
